Last reviewed · How we verify

NCT04726254: JULI

The JULI Registry--Hemp and Cannabis Observational Registry

Status unknown Last updated 19 July 2022
What this trial tests

trial in Chronic Pain in 2,000 participants. Status unknown.

Timeline
1 August 2021
Primary endpoint
15 February 2024
15 February 2025

Quick facts

Lead sponsorJuva Life
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment2,000
Start date1 August 2021
Primary completion15 February 2024
Estimated completion15 February 2025
Sites4 locations across United States

Conditions studied

Sponsor

Juva Life

Who can join

21 and older, any sex, with Chronic Pain or Appetite Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The JuLi Registry seeks to fill some of the gaps associated with the clinical use of CBD (cannabidiol) and other cannabinoid formulations including THC and others. The overarching goal of this Registry is to rapidly advance research and understanding of the use of cannabis and hemp-based formulations, in the clinical community setting, when it is utilized to manage the symptoms of cancer treatment and other underlying health issues. These symptoms include nausea, neuropathy, and sleeplessness and chronic pain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Pain

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04726254.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing